Gene variants predict treatment success for alcoholism medication

Jan 19, 2011

The effectiveness of an experimental treatment for alcoholism depends on the genetic makeup of individuals who receive it, according to a new study supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health. A report of the findings appears online in the American Journal of Psychiatry.

"This study represents an important milestone in the search for personalized treatments for ," says NIAAA Acting Director Kenneth R. Warren, Ph.D.

Researchers led by Bankole Johnson, M.D., Ph.D., professor and chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, Charlottesville, conducted a controlled trial to determine if the medication ondansetron could reduce problem drinking, in alcohol-dependent individuals. Ondansetron is currently used to treat nausea and vomiting, often following chemotherapy. It works by blocking receptors for the brain chemical serotonin.

The current study extends the researchers’ previous work on the role the brain’s serotonin system plays in alcohol misuse. Serotonin mediates many processes in the brain, including the rewarding effects of alcohol. Dr. Johnson’s group has shown that variations in the gene that encodes the serotonin transporter, a protein that regulates the concentration of serotonin between nerve cells, can significantly influence drinking intensity. Specifically, serotonin transporter variants designated as LL and TT have been associated with more severe drinking problems. The researchers have also reported that ondansetron may be an effective therapy for some people with alcoholism.

In this study, Dr. Johnson and his colleagues performed genetic analyses to determine which gene variants were carried by each subject, then randomly assigned each subject to treatment regimens with ondansetron or placebo.

The researchers found that, for subjects with the LL genotype, those receiving ondansetron reduced their average number of daily drinks to less than five, while those receiving placebo continued to have five or more drinks per day. LL subjects who received ondansetron also had significantly more days of abstinence, relative to those who received placebo. Ondansetron’s effects were even more pronounced among individuals who possessed both the LL and TT gene variants, while subjects who lacked the LL variant showed no improvement with ondansetron.

"By being able to do genetic screening beforehand, clinicians can eliminate a great deal of the trial and error approach to prescribing medicine," says Dr. Johnson. "Personalized medicine allows them to better predict a successful treatment option."

Explore further: Early exposure to antidepressants affects adult anxiety and serotonin transmission

Provided by National Institutes of Health

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Researchers uncover gene's role in severity of drinking

Feb 04, 2009

New research from the University of Virginia Health System could help explain why some alcoholics are more severe drinkers than others. A UVA team has found strong evidence that the serotonin transporter gene, SLC6A4, plays ...

Genes determine whether sugar pills work

Dec 03, 2008

It is a well-known fact in drug trials that individuals can respond just as well to placebos, sugar pills, as to the active drug. On the other hand, it is difficult to explain why only certain people get better from placebos. ...

Scientists identify drug to treat opioid addiction

Feb 17, 2009

Scientists at Stanford University School of Medicine have discovered that a commonly available non-addictive drug can prevent symptoms of withdrawal from opioids with little likelihood of serious side effects. The drug, ondansetron, ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.